Lu-134-AHomo sapiens (Human)Cancer cell line

Also known as: Lu134AH, Lu134-AH, Lu134-A-H, LU-134-AH, Lu-134-AH, LU-134-A-H, Lu-134-A-H, NCC-c-Lu-134-A-H, Lu134, Lu-134, LU-134, Lu134A, Lu-134A, LU-134A, LU-134-A, Lu-134-a

🤖 AI SummaryBased on 13 publications

Quick Overview

Human lung cancer cell line with known mutations in DCC and p53 genes.

Detailed Summary

Lu-134-A is a human lung cancer cell line derived from small-cell lung carcinoma. It has been extensively studied for genetic alterations, including mutations in the DCC and p53 genes. Research indicates that this cell line exhibits specific genetic profiles associated with lung cancer progression. The DCC gene shows mutations, and p53 mutations are prevalent, contributing to tumorigenesis. These characteristics make Lu-134-A a valuable model for studying lung cancer mechanisms and therapeutic targets.

Research Applications

Genetic mutation analysisCancer progression studiesTherapeutic target identification

Key Characteristics

DCC gene mutationsp53 mutationsSmall-cell lung carcinoma origin

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1387
Species	Homo sapiens (Human)
Tissue Source	Lung[UBERON:UBERON_0002048]

Donor Information

Age	80
Age Category	Adult
Sex	Male

Disease Information

Disease	Small cell lung cancer
Lineage	Lung
Subtype	Small Cell Lung Cancer
OncoTree Code	SCLC

DepMap Information

Source Type	RIKEN
Source ID	ACH-002051_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Pro278Leu (c.833C>T)	Homozygous	-	PubMed=27270441

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

D13S317

D16S539

D5S818

D7S820

TH01

TPOX

vWA

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Genetic diversity among the present Japanese population: evidence from genotyping of human cell lines established in Japan.

Kasai F., Fukushima M., Miyagi Y., Nakamura Y.

Hum. Cell 37:944-950(2024).

DOI PubMed PMC

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.

Yokota J.

Genes Chromosomes Cancer 52:802-816(2013).

DOI PubMed PMC

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

DOI PubMed PMC

Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.

Nakagawa K., Nomura H., Ishikawa Y.

Lancet 363:775-781(2004).

DOI PubMed

A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers.

Inazawa J.

Am. J. Pathol. 161:207-216(2002).

DOI PubMed PMC

Mutation and expression of the DCC gene in human lung cancer.";

Yokota J.

Neoplasia 2:300-305(2000).

DOI PubMed PMC

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Int. J. Oncol. 15:927-934(1999).

DOI PubMed

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Kohara H., Harada M.

Acta Med. Okayama 53:67-75(1999).

DOI PubMed

Small cell lung cancer can express CD34 antigen.";

Hiraki A., Ueoka H., Harada M.

Anticancer Res. 17:3627-3632(1997).

PubMed

Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines.

Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.

Anticancer Drug Des. 8:417-428(1993).

PubMed

Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.

Kashii T., Mizushima Y., Monno S., Nakagawa K., Kobayashi M.

J. Cancer Res. Clin. Oncol. 120:143-148(1994).

DOI PubMed

Interconversion of biological characteristics of small cell lung cancer depending on culture conditions.

Kato K., Ichinose H., Nagatsu T., Hasegawa T.

Gann 75:1089-1099(1984).

DOI PubMed

Changes in cell characteristics due to culture conditions in cell lines from human small cell lung cancer.

Hirohashi S., Yamaguchi K., Kato K., Ichinose H., Nagatsu T.

Jpn. J. Clin. Oncol. 16:203-212(1986).

DOI PubMed

Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

Saijo N.

Cancer Chemother. Pharmacol. 27:263-270(1991).

DOI PubMed

Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma.

Sugimura T., Terada M., Yokota J.

Oncogene 7:451-457(1992).

PubMed

Analysis of LDH isoenzyme patterns in cell lines of the small cell carcinoma (lung) and retinoblastoma.

Higuchi H., Uei Y.

Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985).

DOI